A Study to Evaluate the Long-term Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis
Key facts
- Where
- Budapest VIII, Debrecen és Szeged, MagyarországSee the 3 sites
- Phase
- 2. fázis
Where in Magyarország
- Semmelweis UniversityBudapest VIII, MagyarországTaking people
- University of DebrecenDebrecen, MagyarországTaking people
- University of SzegedSzeged, MagyarországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Apogee Therapeutics Inc.
- Trial code
- EU 2024-519795-11-00
- Record updated
- 2026. augusztus 18.
- Original description
To evaluate the long-term safety and tolerability of APG777 in patients with moderate-to-severe AD.Read full original descriptionShow less
APG777-202 - A Long-term Extension Study to Evaluate the Safety and Efficacy of APG777 in Patients With Atopic Dermatitis Previously Treated With APG777
To evaluate the long-term safety and tolerability of APG777 in patients with moderate-to-severe AD.
Inclusion: Participants who have completed the Treatment Period in a prior APG777 study and were, in the Investigator’s opinion, compliant with the study protocol; Participants who, in the Investigator’s opinion, would benefit from long-term treatment with APG777; Use the same non-prescription non-medicated emollient/moisturizer of their choice from the last day of the Parent Study and throughout the LTE study.
Exclusion: Participants who have developed an AE while participating in the Parent Study which, in the opinion of the Investigator or of the Medical Monitor, could indicate that continued treatment with APG777 may present an unreasonable risk for the patient; Participants who terminated early from the Parent Study or permanently discontinued the study drug during the Parent Study; Use of any of the prohibited medications from Screening Visit (Visit 1) of the LTE study; Presence of dermatologic conditions and/or comorbidities that might confound the diagnosis of AD and/or interfere with study assessments.